1,500+
Attendees
600+
1-2-1 Meetings
350+
Speakers
90+
Exhibitors
4
Co-located events
KEY SPEAKERS
IMMUNOTHERAPY AGENDA AT A GLANCE
| Day 1 – Tuesday 15th October 2019 | |||
|---|---|---|---|
| Opening Keynotes | |||
| Networking Break | |||
| Plenary roundtable session | |||
| Networking Lunch | |||
| Immune checkpoint modulation | Cell therapy | Tumour microenvironment | Technology showcase |
| Networking Break | |||
| Immune checkpoint modulation | Cell therapy | Tumour microenvironment | Technology showcase |
| Offsite Networking Drinks | |||
| Day 2 – Wednesday 16th October 2019 | ||
|---|---|---|
| Combination therapies | ||
| Networking Break | ||
| Immune checkpoint modulation | Cell therapy |
Combination therapies
Chaired by: Christian Klein, Head of Oncology Programmes, Department Head Cancer Immunotherapy, Roche Innovation Centre Zurich, Roche Pharma Research and Early Development |
| Networking Lunch | ||
| Immune checkpoint modulation | Biomarkers and precision medicine | Manufacture and bioprocessing |
| Networking Break | ||
| Neoantigens | Immunotherapy for solid tumours | Immunotherapy for non-oncology |
| Poster presentation and networking drinks | ||
| Day 3 – Thursday 17th October 2019 | ||
|---|---|---|
| Day 3 plenary session. World leading research | ||
| Networking Break | ||
| Therapeutic vaccines and oncolytics | Immunotherapy for solid tumours | Immunotherapy for non-oncology |
| Networking Lunch | ||
|
Closing plenary
Next generation immunotherapy |
||
| End of congress – see you in 2020! | ||
SESSIONS YOU CAN'T MISS
Targeting the tumour microenvironment – Under every stone sleeps a scorpion
• Targeting the tumour microenvironment – Under every stone sleeps a scorpion
• Resistance mechanisms to antibody effector function are complex
• Understanding target expression is key to effective translation
• mAb format is critical to activity and is particularly relevant when developing mAb to target the tumour microenvironment
Stephen Beers , Associate Professor , University Of Southampton
Combination immunotherapies to maximise efficacy
• Immunotherapy/immuno-Oncology (IO) is a rapidly expanding class of drugs which has created a paradigm shift in the treatment of some cancers.
• Progress in understanding the molecular and cellular determinants of response is providing a framework on which patients will benefit from IO therapy and continues to evolve.
• My talk will focus on how best to modulate an anti-cancer immune response through rational/data driven IO combinations
Robert Wilkinson , Director Of Oncology Research , MedImmune
Engineering bispecific antibodies for combination cancer immunotherapy
• Overview of the application of antibody engineering technologies to generate engineered antibodies for combination cancer immunotherapy
• T cell bispecific antibodies and tumor-targeted 4-1BB agonists • Off-the-shelf alternatives to CAR-T cells
Dr Christian Klein , Head Oncology Programs , Roche Pharmaceutical Research and Early Development
The importance of finding cleaner targets for solid tumours
• Conventional cell surface antigens with high expression across tumours are commonly expressed on normal tissues, creating potential for on-target, off-tumour toxicities when targeted by high-potency oncology compounds.
• Recent clinical trial data from patients with solid tumours that were treated with immune checkpoint inhibitors demonstrate that CD8+ T cells can mediate deep and durable responses in solid tumours.
• How to identify TCRs and pMHC targets involved in mediating complete responses following ICI treatment?
• The most promising approaches to identify pMHC targets and their corresponding TCRs will be discussed
Hanspeter Gerber , SVP & CSO , 3T Biosciences
Immunotherapy combination: how can preclinical models guide the selection of the best combo partner
• Preclinical mouse models are key tools to evaluate the activity of cancer immunotherapies. They are instrumental to understand the mechanism of action of tested compounds, and help identifying rationale combination partners for best anti-tumour efficacy
• Here we show how the Pharmacology Group at the Roche Innovation Centre Zurich has been developing over the past years a cutting-edge mouse models platform for in vivo profiling of immunotherapies and their combinations
• The translational relevance of the preclinical data obtained will be shown
Sara Colombetti , Global Head Oncology Discovery Pharmacology , Roche Innovation Center Zurich
Discovery and development of antibody combinations for cancer immunotherapy
• Development of novel antibodies and more powerful therapeutic combinations for immunotherapy is an intense area of focus.
• Difficult and/or conserved targets, finding antibodies with unique functionality, and generating early PoC are some of the challenges to the development of novel antibody therapeutics.
• Symphogen’s approach to discovery and development of potent antibody combinations for cancer immunotherapy, including examples from our clinical pipeline, will be presented.
Johan Lantto , Project Director, Immuno-Oncology , Symphogen A/S
HERA-CD40L: A unique hexavalent CD40 agonist for cancer immunotherapy
• Represents a novel class of crosslinking independent TNFR superfamily agonists
• Increases pro-inflammatory state of all CD40-expressing cells examined
• Induces antigen-specific T cell activity in vivo
• Shows single-agent anti-tumor efficacy in vivo
• Well tolerated in pilot monkey tox study
Oliver Hill , Vice President, Molecular Biology, Protein Engineering , Apogenix Gmbh
Sign Up for Event Updates
There are two parts to the Festival of Biologics: four conferences covering Antibodies, Immunotherapy, Biosimilars and Clinical Trials and an exhibition featuring solutions for pharma and biotech.
There is a registration fee to attend the conferences. To visit the exhibition is free.
Events
Contact us
To sponsor or exhibit contact:
Derek Cavanagh
+44 (0)207 092 1297
derek.cavanagh@terrapinn.com
To speak:
Joan Shutt
+44 (0)207 092 1134
joan.shutt@terrapinn.com
Organiser
